Emmaus Life Sciences, Inc. (EMMA) stock
EMMAOTCPharmaceutical PreparationsFiscal year ends December 31
$0.05−0.01 (-14.38%)
Close on Oct 19, 2026Market cap $6.03MP/E –Yield –
Emmaus Life Sciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Emmaus Life Sciences's operating income for the twelve months ending Jun 30, 2026 was $4.55M. For fiscal 2025 it was $231.00K. The highest annual figure on record is $3.54M in fiscal 2023.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $231.00K | – |
| FY2024 | Dec 31, 2024 | -$1.89M | -153.5% |
| FY2023 | Dec 31, 2023 | $3.54M | – |
| FY2022 | Dec 31, 2022 | -$6.59M | – |
| FY2021 | Dec 31, 2021 | -$6.13M | – |
| FY2020 | Dec 31, 2020 | -$32.00K | – |
| FY2019 | Dec 31, 2019 | -$4.51M | – |
| FY2017 | Sep 30, 2017 | -$7.10M | – |
| FY2016 | Sep 30, 2016 | -$3.77M | – |
| FY2015 | Sep 30, 2015 | -$2.65M | – |
| FY2014 | Sep 30, 2014 | -$3.82M | – |
| FY2013 | Sep 30, 2013 | -$4.20M | – |
| FY2012 | Sep 30, 2012 | -$4.81M | – |
| FY2011 | Sep 30, 2011 | -$5.29M | – |
| FY2010 | Sep 30, 2010 | -$6.51M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $3.79M | – |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -$823.00K | -200.2% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $886.00K | +52.2% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $695.00K | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$557.00K | -141.1% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $821.00K | +3320.8% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $582.00K | -82.5% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$2.74M | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $1.36M | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $24.00K | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $3.33M | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$1.17M | – |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -$1.42M | – |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -$660.00K | – |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -$1.44M | -398.1% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -$3.07M | – |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | -$4.97M | -1475.3% |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | -$31.00K | -487.5% |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $483.00K | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -$1.62M | -242.4% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $361.00K | – |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | $8.00K | -93.1% |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | -$1.54M | – |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | $1.13M | – |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | -$3.35M | – |
| Q3 FY2019CQ3 2018 | Jun 30, 2019 | $116.00K | – |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | -$2.69M | – |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -$1.55M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -$1.42M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | -$1.44M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | -$1.64M | – |
| Q3 FY2016CQ2 2016 | Jun 30, 2016 | -$809.20K | – |
| Q2 FY2016CQ1 2016 | Mar 31, 2016 | -$690.00K | – |
| Q1 FY2016CQ4 2015 | Dec 31, 2015 | -$624.70K | – |
| Q4 FY2015CQ3 2015 | Sep 30, 2015 | -$533.60K | – |
| Q3 FY2015CQ2 2015 | Jun 30, 2015 | -$556.00K | – |
| Q2 FY2015CQ1 2015 | Mar 31, 2015 | -$780.10K | – |
| Q1 FY2015CQ4 2014 | Dec 31, 2014 | -$779.20K | – |
See a number that looks wrong?